Family Guardians™
Skip to main content

Romosozumab, sold as Evenity, is a bone-building osteoporosis medicine given as monthly injections for one year. It can reduce fracture risk in women with severe osteoporosis after the menopause, but it is not suitable for everyone, particularly people who have had a heart attack or stroke. Here is how it works, who it is for and what to expect.

Key takeaways

  • Evenity is a monoclonal antibody. It blocks sclerostin, which increases new bone formation and reduces bone breakdown.
  • It is a 12-month course. Two injections are given under the skin once a month, a total of 210 mg each month.
  • In England, NICE recommends it for a specific group. Women after the menopause with severe osteoporosis who have had a major fracture in the past 24 months.
  • Heart and stroke history matters. It must not be used after a heart attack or stroke, and cardiovascular risk is assessed first.
  • A follow-on medicine is essential. After 12 months, treatment moves to a bone-protecting medicine to keep the gains.

Evenity is one of several osteoporosis injections, and it is unusual because it works in two directions at once. That makes it one of the more powerful options available, which is also why it is reserved for people at the highest risk.

How does Evenity work?

Bone is constantly being broken down and rebuilt. Sclerostin is a protein produced by bone cells that acts as a brake on bone formation. Romosozumab is a laboratory-made antibody that binds to sclerostin and blocks it.

Releasing that brake increases the activity of bone-forming cells. Romosozumab also reduces bone breakdown. This dual effect is different from denosumab and the bisphosphonates, which mainly slow breakdown, and from teriparatide, which mainly stimulates formation.

A consultant talking with an older woman in a consulting room.

Who is Evenity for?

In the UK, romosozumab is licensed for severe osteoporosis in women after the menopause who are at high risk of fracture. NICE guidance for England is narrower. It recommends romosozumab only if the person has had a major osteoporotic fracture (spine, hip, forearm or humerus) within the past 24 months, meaning they are at imminent risk of another fracture.

This reflects how fracture risk works in practice: the period soon after a fracture carries the greatest risk of another one. A medicine that acts quickly is most valuable during that window. Your FRAX score, DEXA results and fracture history all inform the decision.

Who should not have Evenity?

Romosozumab must not be used in people who have had a heart attack (myocardial infarction) or stroke. It is also not used in people with low blood calcium, which must be corrected first.

In a large trial comparing romosozumab with alendronic acid, heart attacks and strokes were reported more often in the romosozumab group. Because of this, your clinician should assess your cardiovascular risk, including blood pressure, cholesterol, diabetes and smoking, and weigh it against your fracture risk before starting. If a heart attack or stroke occurs during treatment, romosozumab is stopped.

How is Evenity given?

Each monthly dose is 210 mg, given as two separate injections of 105 mg under the skin, usually in the abdomen, thigh or upper arm. The course lasts 12 months. Treatment should be started and supervised by a clinician experienced in managing osteoporosis.

You will usually be advised on adequate calcium and vitamin D intake before and during treatment. Tell your team about any dental problems or planned dental work, and about all other medicines and supplements you take.

What are the side effects?

In clinical trials, the most common side effects were cold-like symptoms (nasopharyngitis), reported by about 14 in 100 people, and joint pain (arthralgia), reported by about 12 in 100. Reactions at the injection site, such as redness or discomfort, can also occur.

Less common but important risks include:

  • Low blood calcium: seek advice if you notice muscle spasms, twitching, cramps or numbness around the mouth or in the fingers.
  • Jaw problems: rare cases of osteonecrosis of the jaw have been reported. Report persistent mouth pain, loose teeth or non-healing sores.
  • Unusual thigh fractures: report new or unusual pain in the hip, groin or thigh.
  • Allergic reactions: rarely, serious allergic reactions have been reported. Swelling of the face or throat or difficulty breathing needs emergency help.

What does the evidence show?

In the ARCH trial, women with severe osteoporosis and previous fractures received either romosozumab for 12 months followed by alendronic acid, or alendronic acid throughout. The romosozumab-first group had significantly fewer new spinal, non-spinal and hip fractures.

The same trial reported more serious cardiovascular events with romosozumab: heart attacks in 0.8% versus 0.2%, and strokes in 0.6% versus 0.3% in the first year. These findings explain both the medicine’s value and its restrictions.

An older woman walking in a London park in autumn.

What happens after 12 months?

The bone-building effect of romosozumab does not last on its own. After the course, a bone-protecting medicine such as alendronic acid, zoledronic acid or denosumab should be started without delay to maintain and extend the benefit. This plan should be agreed before the first injection.

Evenity vs Prolia: what is the difference?

Both are monoclonal antibodies given as injections, but they are used differently. Prolia (denosumab) mainly slows bone breakdown, is given every six months and is usually continued long term. Evenity builds bone as well as slowing breakdown, is given monthly for a fixed 12 months and is reserved for severe osteoporosis at very high, imminent fracture risk. For some people, Prolia may be the medicine used after an Evenity course.

Frequently asked questions

How long does Evenity take to work?

Romosozumab acts quickly on bone formation, and trials showed fewer fractures within the first year. Your clinician may repeat a DEXA scan after the course to assess your response.

Can men have Evenity?

In the UK, Evenity is licensed for women after the menopause. Men with osteoporosis have other treatment options, including bone-building medicines in some circumstances.

Can Evenity be given more than once?

The licensed course is 12 monthly doses. Repeating a course is not standard practice, which is why the follow-on treatment plan is so important.

Is Evenity available on the NHS?

In England, NICE recommends romosozumab for women after the menopause with severe osteoporosis who have had a major osteoporotic fracture in the past 24 months. Access in practice depends on local specialist services.

Is Evenity the same as Prolia?

No. Both are injected antibody medicines, but Evenity builds bone for a fixed 12-month course, while Prolia slows bone loss and is given every six months, usually long term.

Find out whether you could benefit

If you have had a recent fracture or have been told you have severe osteoporosis, London Osteoporosis Clinic can review your fracture risk, heart and stroke history and previous treatment, and discuss whether a bone-building medicine is appropriate. Arrange a consultant appointment or check the current consultation fees.


Written by Dr Taher Mahmud, Consultant Rheumatologist and Co-Founder, London Osteoporosis Clinic.

This article provides general information and does not replace advice from your own clinician. Do not start, stop or change osteoporosis treatment based on this article. Seek emergency care for chest pain, stroke symptoms or a severe allergic reaction.

References and further reading

  1. National Institute for Health and Care Excellence. Romosozumab for treating severe osteoporosis (TA791); accessed 18 November 2026.
  2. UCB Pharma. Evenity 105 mg summary of product characteristics; accessed 18 November 2026.
  3. National Osteoporosis Guideline Group. Pharmacological treatment options; accessed 18 November 2026.
  4. Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med, 2017.

Get Latest Updates

Leave a Reply

×